Adjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett’s Esophagus: A Systematic Review and Meta-Analysis
While aberrant p53 expression has been associated with an increased risk of progression to advanced neoplasia in BE patients undergoing surveillance, the diagnostic characteristics are suboptimal precluding uniform clinical adoption. Prospective studies with standardized grading protocols are needed to determine whether p53-guided surveillance strategies can meaningfully improve patient outcomes.
Authors
- Perica Davitkov
- Margaret Zhou (ORCID: https://orcid.org/0000-0002-9111-1659)
- Tarek Sawas (ORCID: https://orcid.org/0000-0002-0025-9827)
- David A. Katzka (ORCID: https://orcid.org/0000-0003-2307-2317)
- Aaron P Thrift
- David A. Leiman
- Swathi Eluri
- Matthew D. Stachler
- Siddharth Singh
- Joel H. Rubenstein
Institutions
- Duke University (US)
- University of California, San Francisco (US)
- Baylor College of Medicine (US)
- University of Utah (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- Jacksonville College (US)
- University of California San Diego (US)
- Clinical Research Institute (US)
- VA Center for Clinical Management Research (US)
- Michigan Cancer Research Consortium (US)
- University of Colorado Anschutz Medical Campus (US)
- Columbia University (US)
- The University of Texas Southwestern Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2026-02-25
- DOI
- https://doi.org/10.14309/ajg.0000000000003977
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00